This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weih, M. Articles by Einhäupl, K. Search for Related Content PubMed PubMed Citation Articles by Weih, M. Articles by Einhäupl, K. Related Collections Other diabetes Acute Cerebral Infarction Risk Factors for Stroke Receptor pharmacology

(Stroke. 2001;32:2029.)
© 2001 American Heart Association, Inc.

Original Contributions

Sulfonylurea Drugs Do Not Influence Initial Stroke Severity and In-Hospital Outcome in Stroke Patients With Diabetes

Markus Weih, MD; Nicola Amberger; Susanne Wegener, MD; Ulrich Dirnagl, MD; Thomas Reuter, MD Karl Einhäupl, MD

From the Department of Neurology and Department of Hepatology and Gastroenterology (T.R.), Charite Hospital, Humboldt University Berlin (Germany).

Correspondence to Dr Markus Weih, Neurological Intensive Care Unit, Department of Neurology, Charite Hospital, Humboldt University Berlin, Schumannstrasse 20-21, 10098 Berlin, Germany.

Background and Purpose—— Sulfonylurea drugs inhibit ATP-dependent potassium channels and may increase mortality after myocardial infarction. Sulfonylurea drugs also inhibit ischemic preconditioning in experimental models of brain ischemia and in clinical studies in the human heart.

Methods—— In the present study we examined the impact of sulfonylurea drugs on in-hospital mortality and the immediate neurological deficit of diabetic stroke patients. From a larger stroke data bank, we studied 146 diabetic patients with acute hemispheric ischemic stroke. Sixty patients were using sulfonylurea drugs.

Results—— Major baseline characteristics such as age, blood pressure, admission glucose level, HbA_1c, distribution of cardiovascular risk factors, and presumed stroke etiology (Trial of Org 10172 in Acute Stroke Treatment [TOAST] criteria) were not different. Mortality (15% versus 14%; P=0.86) and initial stroke severity (Canadian Neurological Scale score, 7.4 versus 7.5; P=0.79) were not significantly different between patients with and without sulfonylurea drugs. Further end points such as Rankin Scale score, deteriorating stroke, duration of hospital stay, type of infarcts on CT/MRI, requirement of intensive care, and complications were not different. In a stepwise logistic regression model, sulfonylurea drugs were not independent predictors for increased mortality, deteriorating stroke, or stroke severity.

Conclusions—— In the present hospital-based study, sulfonylurea drugs in patients with diabetes and stroke are not associated with increased stroke severity, mortality, or a worse in-hospital outcome.

Key Words: cerebral ischemia • clinical study • hypoxia • preconditioning

This article has been cited by other articles:

				H. Kunte, S. Schmidt, M. Eliasziw, G. J. del Zoppo, J. M. Simard, F. Masuhr, M. Weih, and U. Dirnagl Sulfonylureas Improve Outcome in Patients With Type 2 Diabetes and Acute Ischemic Stroke Stroke, September 1, 2007; 38(9): 2526 - 2530. [Abstract] [Full Text] [PDF]

				A. Arboix Potential Impact of Sulfonylureas in the Outcome of Type 2 Diabetic Patients With Ischemic Stroke Stroke, September 1, 2007; 38(9): 2413 - 2414. [Full Text] [PDF]

				P. Valensi and G. Slama Review: Sulphonylureas and cardiovascular risk: facts and controversies The British Journal of Diabetes & Vascular Disease, July 1, 2006; 6(4): 159 - 165. [Abstract] [PDF]

				S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch Management of Diabetes and Hyperglycemia in Hospitals Diabetes Care, February 1, 2004; 27(2): 553 - 591. [Full Text] [PDF]